The State of the Art of Investigational and Approved Nanomedicine Products for Nucleic Acid Delivery

2019 
Abstract The use of nanoparticles in drug delivery is increasing greatly because they offer several advantages including enhanced pharmacokinetic drug profile, site selective targeting, controlled and sustained release of drugs, and reduced toxicity. The present chapter offers an up-to-date analysis (late 2018) of nanodrugs translational context by summarising the nanoformulations approved by the FDA (Food and Drug Administration) and EMA (European Medicines Agency), and providing information regarding the nanocarriers currently undergoing to phase I, phase II, phase III, or phase IV clinical trials. The nanovectors have been divided into two major classes according to their use: gene therapy nanocarriers (nucleic acid delivery) and other nanocarriers. Moreover, they have also been subclassified according to their composition: polymeric micelles, viruses and inorganic, protein, polymeric, crystalline, and lipid-based nanoparticles.
    • Correction
    • Source
    • Cite
    • Save
    • Machine Reading By IdeaReader
    0
    References
    2
    Citations
    NaN
    KQI
    []